Cellular reprogramming and the rise of rejuvenation biotech

João Pedro De Magalhães; Alejandro Ocampo

doi:10.1016/j.tibtech.2022.01.011

Cellular reprogramming and the rise of rejuvenation biotech

João Pedro De Magalhães, Alejandro Ocampo

Inflammation and Ageing

Research output: Contribution to journal › Short survey › peer-review

238 Downloads (Pure)

Abstract

Cells can be rejuvenated and biological clocks reset using cellular reprogramming. A growing number of companies now aim to use cellular reprogramming to develop therapies for rejuvenating human beings. Can the ‘young’ science of rejuvenation, currently mostly based on in vitro studies, drive a new biotech field toward clinical applications?

Original language	English
Pages (from-to)	639-642
Number of pages	4
Journal	Trends in Biotechnology
Volume	40
Issue number	6
Early online date	18 Feb 2022
DOIs	https://doi.org/10.1016/j.tibtech.2022.01.011
Publication status	Published - Jun 2022

Bibliographical note

Funding Information:
Work in the lab of J.P.M. is supported by grants from the Wellcome Trust (208375/Z/17/Z), LongeCity, and the Biotechnology and Biological Sciences Research Council (BB/R014949/1 and BB/V010123/1). J.P.M. is an advisor/consultant for the Longevity Vision Fund, Centaura, NOVOS, YouthBio Therapeutics and the founder of Magellan Science Ltd, a company providing consulting services in longevity science. A.O. is founder of Longevity Consultancy Group, a company providing consulting services in longevity science.

Publisher Copyright:
© 2022 Elsevier Ltd

Keywords

Yamanaka factors
aging
gene therapy
longevity

ASJC Scopus subject areas

Biotechnology
Bioengineering

Access to Document

10.1016/j.tibtech.2022.01.011

DeMagalhãesj2022CellularAccepted author manuscript, 242 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

https://linkinghub.elsevier.com/retrieve/pii/S0167779922000257

Cite this

@article{69414200a8bd4ae0a4711aba98a1a0d3,

title = "Cellular reprogramming and the rise of rejuvenation biotech",

abstract = "Cells can be rejuvenated and biological clocks reset using cellular reprogramming. A growing number of companies now aim to use cellular reprogramming to develop therapies for rejuvenating human beings. Can the {\textquoteleft}young{\textquoteright} science of rejuvenation, currently mostly based on in vitro studies, drive a new biotech field toward clinical applications?",

keywords = "Yamanaka factors, aging, gene therapy, longevity",

author = "{De Magalh{\~a}es}, {Jo{\~a}o Pedro} and Alejandro Ocampo",

note = "Funding Information: Work in the lab of J.P.M. is supported by grants from the Wellcome Trust (208375/Z/17/Z), LongeCity, and the Biotechnology and Biological Sciences Research Council (BB/R014949/1 and BB/V010123/1). J.P.M. is an advisor/consultant for the Longevity Vision Fund, Centaura, NOVOS, YouthBio Therapeutics and the founder of Magellan Science Ltd, a company providing consulting services in longevity science. A.O. is founder of Longevity Consultancy Group, a company providing consulting services in longevity science. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = jun,

doi = "10.1016/j.tibtech.2022.01.011",

language = "English",

volume = "40",

pages = "639--642",

journal = "Trends in Biotechnology",

issn = "0167-7799",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Cellular reprogramming and the rise of rejuvenation biotech

AU - De Magalhães, João Pedro

AU - Ocampo, Alejandro

N1 - Funding Information: Work in the lab of J.P.M. is supported by grants from the Wellcome Trust (208375/Z/17/Z), LongeCity, and the Biotechnology and Biological Sciences Research Council (BB/R014949/1 and BB/V010123/1). J.P.M. is an advisor/consultant for the Longevity Vision Fund, Centaura, NOVOS, YouthBio Therapeutics and the founder of Magellan Science Ltd, a company providing consulting services in longevity science. A.O. is founder of Longevity Consultancy Group, a company providing consulting services in longevity science. Publisher Copyright: © 2022 Elsevier Ltd

PY - 2022/6

Y1 - 2022/6

N2 - Cells can be rejuvenated and biological clocks reset using cellular reprogramming. A growing number of companies now aim to use cellular reprogramming to develop therapies for rejuvenating human beings. Can the ‘young’ science of rejuvenation, currently mostly based on in vitro studies, drive a new biotech field toward clinical applications?

AB - Cells can be rejuvenated and biological clocks reset using cellular reprogramming. A growing number of companies now aim to use cellular reprogramming to develop therapies for rejuvenating human beings. Can the ‘young’ science of rejuvenation, currently mostly based on in vitro studies, drive a new biotech field toward clinical applications?

KW - Yamanaka factors

KW - aging

KW - gene therapy

KW - longevity

UR - http://www.scopus.com/inward/record.url?scp=85124901810&partnerID=8YFLogxK

U2 - 10.1016/j.tibtech.2022.01.011

DO - 10.1016/j.tibtech.2022.01.011

M3 - Short survey

SN - 0167-7799

VL - 40

SP - 639

EP - 642

JO - Trends in Biotechnology

JF - Trends in Biotechnology

IS - 6

ER -

Cellular reprogramming and the rise of rejuvenation biotech

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this